Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 4/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5719346 | 0.90 | LMNA (0.46) | DPP4L3MBTL1ALDH1A1LMNATSHR | |
| Trifluoroacetic Acid SCHEMBL5773381 | 0.89 | DPP4 (0.46) | DPP4L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL5788736 | 0.88 | LMNA (0.48) | DPP4L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL5774800 | 0.88 | DPP4 (0.50) | DPP4L3MBTL1ALDH1A1LMNATSHR | |
| Trifluoroacetic Acid SCHEMBL5719367 | 0.88 | DPP4 (0.45) | DPP4L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL5789482 | 0.87 | DPP4 (0.50) | DPP4L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL6383694 | 0.84 | DPP4 (0.40) | DPP4L3MBTL1ALDH1A1LMNATSHR | |
| Trifluoroacetic Acid SCHEMBL5719238 | 0.84 | DPP4 (0.52) | DPP4L3MBTL1ALDH1A1LMNATSHR | |
| Acetic Acid SCHEMBL6383692 | 0.84 | DPP4 (0.42) | DPP4L3MBTL1ALDH1A1LMNATSHR | |
| SCHEMBL5770332 | 0.84 | DPP4 (0.39) | DPP4L3MBTL1ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | DPP4 1/4885L3MBTL1 1200/4885ALDH1A1 112/4885 |
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | DPP4 1/4885L3MBTL1 4196/4885ALDH1A1 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.